On August 7, 2020, the FDA approved Genentech’s Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Evrysdi showed clinically-meaningful improvements in motor function across two clinical trials in people with varying ages and levels of disease severity, including Types 1, 2, and 3 SMA. A liquid medicine, Evrysdi is administered daily at home by mouth or feeding tube.
Learn how advancing science is helping address unmet needs in the spinal muscular atrophy (SMA) community.
These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.
Please see full Prescribing Information for additional Important Safety Information.
“Given the majority of people with SMA in the U.S. remain untreated, we believe Evrysdi, with its favorable clinical profile and oral administration, may offer meaningful benefits for many living with this rare neurological disease.”